* Genzyme Molecular Oncology, of Cambridge, Mass., began trading Monday on Nasdaq under the ticker symbol GZMO. Parent company Genzyme Corp., also of Cambridge, distributed many of the 12.7 million shares as a tax-free dividend to Genzyme General shareholders, who received 0.10805 share of Genzyme Molecular per share of Genzyme General. Fractional shares were converted to cash at a rate of $7 per share.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Pantheco A/S, of Copenhagen, Denmark, inked a sublicensing deal, giving Pantheco rights to Isis' Peptide Nucleic Acid (PNA) technology for the creation of anti-infective drugs. Isis gains a 24.9 percent equity position in Pantheco and retains rights to all other areas of human therapeutics. Pantheco is a new company, established to develop PNA-based drugs for bacterial infections. The firm has raised $12.3 million and will commence operations Jan. 1.
* Organogenesis Inc., of Canton, Mass., has completed enrollment in a pivotal trial of Apligraf for diabetic ulcers in more than 200 patients. The skin substitute is already approved for venous ulcers, and Organogenesis expects to begin the registration process for the new indication in the second half of 1999.